Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Status:
Completed
Trial end date:
2020-02-24
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled, 3-way cross-over phase IIa trial comparing two dose
levels of THN102 to placebo in patients suffering from Parkinson's disease associated with
excessive daytime sleepiness.